• Adenovirus Service • AAV Service • Lentivirus Service • Retrovirus Service
CpG oligodeoxynucleotides (CpG ODN) are immunomodulatory synthetic oligonucleotides that specifically stimulate Toll-like receptor 9 (TLR9), inducing cellular and humoral immune responses to enhance the body's immune defense. After infection, pathogen-expressed evolutionarily conserved molecular structures can trigger innate immune responses. These structures are known as pathogen-associated molecular patterns (PAMPs) and are recognized by host TLRs. PAMPs such as lipopolysaccharides and lipoproteins are recognized by TLR4 and TLR2; bacterial flagellin by TLR5; double-stranded RNA (dsRNA) by TLR3; single-stranded RNA (ssRNA) by TLR7/8; and unmethylated CpG motifs present in bacterial and viral DNA by TLR9.
Human monoclonal antibodies are a diverse class of therapeutic drugs that, in theory, can target any protein with extremely high specificity, making them highly promising candidates for treating a wide range of diseases. Until recently, antibody development primarily relied on discovery-based experimental methods, typically involving screening human or animal samples previously exposed to the antigen target of interest. Even with significant improvements in the throughput of antibody discovery methods, this process remains laborious, slow, and cost-ineffective. The continued expansion of the therapeutic market and the scope of monoclonal antibody applications has increased the demand for computational tools that can accelerate and expand antibody discovery capabilities.
Globally, approximately one in six couples face infertility issues, with about one-third of these cases having no known cause. Although in vitro fertilization (IVF) has become a significant solution, the success rate remains around 30%, with embryo quality being a major limiting factor. Traditional views often attribute fertility problems more to women, but recent research has found that small RNA (sRNA) molecules carried by sperm are subtly influencing the ultimate fate of the embryo.
The 2025 Nobel Prize in Physiology or Medicine was awarded to Mary Brunkow, Fred Ramsdell, and Shimon Sakaguchi for their discovery and definition of regulatory T cells (Treg cells), revealing their importance in controlling autoreactive responses and pioneering the new field of Treg cell-mediated peripheral immune tolerance.
In the field of lung cancer treatment, targeted therapies against epidermal growth factor receptor (EGFR) mutations, such as third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs) like osimertinib, have brought about revolutionary breakthroughs.However, like many precision therapies, drug resistance remains a persistent problem. Although the initial efficacy is significant, tumor cells quickly enter a state of drug tolerance and persistence (DTP), or eventually develop complete resistance, leading to tumor residue and recurrence. This has become a major challenge for clinicians.
A recent study published in the journal Science has revealed a cellular mechanism for the transmission of genetic mutations and points to a potential treatment that could reduce the risk of infants developing severe and incurable mitochondrial diseases.
CAR-T cell therapy has shown significant efficacy in treating hematologic malignancies such as leukemia and lymphoma, prompting research into its application in various solid tumors. Among these tumors, glioblastoma (GBM) stands out as a particularly challenging target due to its aggressive nature and the lack of effective treatment options.
Environmental, social, and genetic factors contribute to overeating and reduced physical activity, leading to weight gain. Over time, weight gain is often associated with the development of hypertension, dyslipidemia, and cardiovascular disease. Obesity-related dyslipidemia is characterized by elevated serum triglyceride (TG) levels, elevated low-density lipoprotein (LDL) cholesterol levels, and low high-density lipoprotein (HDL) cholesterol levels. This lipid profile has a pro-atherosclerotic effect. However, the mechanisms by which obesity causes changes in lipid levels remain unclear.
Liver cancer treatment has always been a clinical challenge. Traditional treatments often yield limited effectiveness due to rapid tumor progression and high molecular heterogeneity. Finding targets that simultaneously address tumor metabolism and immune evasion has become crucial for overcoming treatment bottlenecks. Recently, Hepatology published a new study by a team from the University of Hong Kong titled "Targeting sterol O-acyltransferase 1 rewires fatty acid metabolism and uncovers immune vulnerability in hepatocellular carcinoma." They focused on sterol O-acyltransferase 1 (SOAT1), discovering that this protein is not only a metabolic vulnerability point in liver cancer but also regulates the tumor immune microenvironment, bringing a new "two-pronged" strategy to liver cancer treatment.
Hepatocellular carcinoma (HCC) is the fourth most common cancer worldwide and the second leading cause of cancer-related death. Clinically, HCC is often diagnosed at an advanced stage, leaving patients with limited treatment options. Recently, immune checkpoint blockade (ICB) therapy using monoclonal antibodies targeting PD-1, PD-L1, or CTLA-4 has emerged as a promising treatment approach for HCC. However, the unique liver environment significantly reduces HCC's response to ICB therapy, and resistance often develops, resulting in an overall benefit rate of only 15%-20%.
